cd3/cd28 stimulated t cells
Cell therapyexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2008 (NCT00674427)
Timeline
Indications
Studied for
- Hodgkin Disease · Phase 1/Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1/Phase 2
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Multiple Myeloma · Phase 2
- Myelodysplastic Syndromes · Phase 1/Phase 2
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1/Phase 2
Mechanism of action
- T-lymphocytesImmunity, passive
T-lymphocytes immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cd3/cd28 activated t cells
- cd3/cd28 stimulated t cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01426828 | Phase 2 | Aug 1, 2011 | University of Pennsylvania, University of Texas at Houston |
| NCT01013441 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2009 | University of Pennsylvania, University of Texas at Houston |
| NCT00674427 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2008 | University of Pennsylvania |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Pennsylvania | Academic/Hospital | 3 | 3 | 1 | 2008 |
| University of Texas at Houston | Academic/Hospital | 2 | 0 | 1 | 2009 |
2 organizations
Page 1 / 1